Home Ingredients Capsifen® (Bioavailable Capsaicinoids via FenuMat® — Akay Bioactives)
Weight ManagementMetabolic Health

Capsifen® (Bioavailable Capsaicinoids via FenuMat® — Akay Bioactives)

Capsicum annum
Evidence Level
Strong
2 Clinical Trials
6 Documented Benefits
4/5 Evidence Score

Capsifen is Akay Bioactives' red chili (Capsicum annum) capsaicinoid complex delivered via FenuMat technology, fenugreek galactomannan beadlets that encapsulate capsaicinoids in self-emulsifying hydrogel form. Standardized to 2.1% total capsaicinoids (capsaicin + dihydrocapsaicin + nordihydrocapsaicin). The FenuMat delivery provides 19× higher serum bioavailability of 'free' (unconjugated) capsaicinoids vs standard capsaicin extracts, with pungency masked, solving the fundamental challenge of capsaicinoid supplementation (burning sensation and stomach discomfort at effective doses). In a randomized double-blind placebo-controlled crossover in healthy overweight participants, 100 mg and 200 mg doses produced dose-dependent weight reductions, increased energy expenditure, fat oxidation, endurance, and body temperature elevation, with no increased heart rate, palpitations, sweating, or abdominal pain. Honest framing: a well-designed recent trial in a relevant population; the bioavailability and tolerability advantages over plain capsaicin are clinically meaningful.

Studied Dose 100-200 mg/day.
Active Compound Capsicum annum (red chili) capsaicinoid extract; standardized to 2.1% total capsaicinoids (capsaicin, dihydrocapsaicin, nordihydrocapsaicin).

Benefits

Dose-dependent weight reduction

Dose-dependent weight reduction in a randomized double-blind placebo-controlled crossover trial in healthy overweight participants: 4.8% weight reduction at 100 mg/day Capsifen and 6.2% at 200 mg/day vs baseline. Clear dose-response.

Supported by Trial 1

Increased energy expenditure

Increased energy expenditure was documented at both Capsifen doses vs placebo, measured via a validated cardiopulmonary exercise test system. Increased EE is the primary mechanism through which capsaicinoids influence body weight, increased calorie burn rather than appetite suppression.

Supported by Trial 1, Trial 2

Enhanced fat oxidation

Respiratory quotient analysis revealed reductions in both resting and exercise-induced RQ values in Capsifen groups, indicating shifted substrate utilization toward fat oxidation vs carbohydrate oxidation. A mechanism for body composition changes beyond simple energy balance.

Supported by Trial 1, Trial 2

Improved endurance performance

Time to exhaustion (endurance) significantly improved in Capsifen groups vs placebo. Positions Capsifen as a dual-use ergogenic aid, useful for both weight management and athletic performance support.

Supported by Trial 1

19× higher free capsaicinoid bioavailability

FenuMat delivery achieves 19× higher serum bioavailability of 'free' (unconjugated, bioactive) capsaicinoids vs standard capsaicin extracts. The 'free' fraction matters because conjugated capsaicin metabolites have reduced biological activity. This enables clinical efficacy at the low 100-200 mg/day doses with masked pungency.

Supported by Trial 1, Trial 2

Pungency-free with no GI adverse events

Critical practical advantage: no increased heart rate, palpitations, sweating, or abdominal pain reported despite clear thermogenic efficacy (+1-2°C body temperature elevation). FenuMat beadlets enable sustained intestinal release that bypasses the gastric irritation that limits standard capsaicin supplementation.

Supported by Trial 1

Mechanism of action

1

TRPV1 receptor activation (thermogenesis)

Capsaicinoids activate the TRPV1 (vanilloid receptor 1) thermal-sensing ion channel in sensory neurons. Activation triggers sympathetic nervous system activity and brown adipose tissue thermogenesis — the body's primary metabolic heat generation mechanism. Drives the +1-2°C body temperature elevation and increased energy expenditure.

2

Fat oxidation pathway upregulation

TRPV1 activation upregulates fatty acid oxidation enzymes (CPT1, ACO) and downregulates lipogenesis. Net effect: more fat used as fuel, less stored. Measurable in the Roopashree trial as reduced respiratory quotient (more fat vs carbs oxidized).

3

Catecholamine release

Capsaicinoid-triggered sympathetic activation releases catecholamines (norepinephrine, epinephrine) which mobilize fatty acids from adipose tissue and increase basal metabolic rate. The same pathway underlies caffeine and other thermogenic ingredients, but capsaicin operates via a distinct receptor (TRPV1) without adenosine antagonism.

4

FenuMat sustained intestinal release

Fenugreek galactomannan beadlets form a self-emulsifying hydrogel in the intestinal environment, delivering capsaicinoids slowly to the small intestinal lumen — bypassing the gastric mucosa where direct capsaicin exposure causes the characteristic burn. Sustained release also extends the duration of TRPV1 stimulation.

Clinical trials

1
Capsifen 28-Day Crossover Trial

Randomized double-blind placebo-controlled 3-arm 3-sequence crossover trial in 105 healthy overweight adults. Arms: placebo, Capsifen 100 mg/day, Capsifen 200 mg/day, each for 28 days.

105 healthy overweight adults

Randomized double-blind placebo-controlled 3-arm 3-sequence crossover trial in 105 healthy overweight adults. Arms: placebo, Capsifen 100 mg/day, Capsifen 200 mg/day, each for 28 days. Outcomes: dose-dependent weight reduction (4.8% and 6.2%), increased energy expenditure, increased fat oxidation (reduced respiratory quotient), improved time to exhaustion, body temperature elevation +1-2°C. No adverse events including no tachycardia, palpitations, sweating, or GI symptoms. Published in Frontiers in (doi:10.3389/fnut.2024.1348328).

2
Capsifen Safety Assessment

Acute (14-day) and sub-chronic (90-day) toxicity studies in Wistar rats.

Clinical population described in trial publication.

Acute (14-day) and sub-chronic (90-day) toxicity studies in Wistar rats. Capsifen administration produced no significant changes in food/water consumption, hematological or biochemical parameters. Histopathology showed no morphological abnormalities. Body weight showed mild decreasing trend at high doses (500-1,000 mg/kg) consistent with thermogenic mechanism. Established safety basis for human clinical trials.

Side effects and drug interactions

Common Potential side effects

Excellent tolerability profile in the Roopashree 2024 trial — no GI symptoms, no cardiovascular adverse events.
Fenugreek allergy concern — FenuMat is fenugreek-derived; individuals with fenugreek/legume allergy should avoid.
Theoretical sensitivity to capsaicinoids in individuals with active GERD, peptic ulcer disease, or IBS flares (though sustained intestinal release reduces this concern vs standard capsaicin).
Mild body temperature elevation expected — feature of the mechanism, not a side effect.
Pregnancy and lactation — safety data lacking; avoid.

Important Drug interactions

Antihypertensives — capsaicinoids modestly activate sympathetic nervous system; theoretical interaction with blood pressure medications; monitor BP if combined.
Stimulant medications — additive sympathomimetic effects possible with caffeine, ephedrine, ADHD medications; use caution.
Anticoagulants — capsaicinoids may have mild antiplatelet activity; monitor INR with warfarin.
ACE inhibitors — rare reports of cough exacerbation with high capsaicin intake.
Pregnancy and lactation — avoid; safety not established at supplemental doses.

More Weight Management Ingredients

Weight Management
Capsaicin / Capsicum Extract (Cayenne Pepper)
Capsicum extract (cayenne pepper, red chili pepper) and its primary bioactive capsaicin ar…
Weight Management
Glucomannan (Konjac Root Fiber)
Glucomannan is a water-soluble dietary fiber derived from the root of the konjac plant (Am…
Weight Management
Supresa® (Saffron Extract for Appetite & Crave Control — PLT Health)
Supresa is PLT Health Solutions' patented saffron (Crocus sativus L.) stigma extract, clin…
Weight Management
Erythritol
Erythritol is a 4-carbon sugar alcohol (polyol) — about 60-70% as sweet as sucrose with es…

Explore Other Ingredients

Athletic Performance
L-Carnitine
L-Carnitine is a naturally-occurring amino acid derivative essential for fatty acid metabo…
Antioxidant
Dandelion Root
Dandelion root is a traditional herb used to support liver and digestive health and as a g…
Cognitive
Vitamin B12
Vitamin B12, also known as cobalamin, is a water-soluble vitamin commonly supplemented as…

Frequently asked questions about Capsifen® (Bioavailable Capsaicinoids via FenuMat® — Akay Bioactives)

What is Capsifen?

Capsifen is Akay Bioactives' red chili (Capsicum annum) capsaicinoid complex delivered via FenuMat technology, fenugreek galactomannan beadlets that encapsulate capsaicinoids in self-emulsifying hydrogel form. Standardized to 2.1% total capsaicinoids (capsaicin + dihydrocapsaicin + nordihydrocapsaicin).

What is Capsifen used for?

Capsifen is researched primarily for Weight Management and Metabolic Health. Dose-dependent weight reduction in a randomized double-blind placebo-controlled crossover trial in healthy overweight participants: 4.8% weight reduction at 100 mg/day Capsifen and 6.2% at 200 mg/day vs baseline. Clear dose-response.

What is the recommended dosage of Capsifen?

The clinically studied dose is 100-200 mg/day. Always follow the product label and check with a healthcare provider for personal advice.

Is Capsifen safe, and does it have side effects?

For most healthy adults, Capsifen is well tolerated at studied doses. Reported effects can include: Excellent tolerability profile in the Roopashree 2024 trial — no GI symptoms, no cardiovascular adverse events. Fenugreek allergy concern — FenuMat is fenugreek-derived; individuals with fenugreek/legume allergy should avoid. It may also interact with some medications. Capsifen is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Does Capsifen interact with any medications?

Possible interactions include: Antihypertensives — capsaicinoids modestly activate sympathetic nervous system; theoretical interaction with blood pressure medications; monitor BP if combined. If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for Capsifen?

NutraSmarts rates the evidence for Capsifen as Strong (4 out of 5). It is backed by 2 clinical trials and 4 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(4 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Roopashree N, Syam DS, Krishnakumar IM, Mala KN, Fleenor BS, Thomas J. A natural sustained-intestinal release formulation of red chili pepper extracted capsaicinoids (Capsifen) safely modulates energy balance and endurance performance: a randomized, double-blind, placebo-controlled study. Front Nutr. 2024;11:1348328. doi: 10.3389/fnut.2024.1348328.PubMedUsed to support: Manufacturer-funded RCT (n=105 adults with obesity) of the actual Capsifen ingredient; 100-200 mg/day for 28 days produced dose-dependent increases in resting and exercise energy expenditure, fat oxidation, and endurance with modest body-weight reduction, directly backing the thermogenesis/energy-expenditure claims (industry-funded by the ingredient maker).
  2. Irandoost P, Lotfi Yagin N, Namazi N, Keshtkar A, Farsi F, Mesri Alamdari N, et al. The effect of Capsaicinoids or Capsinoids in red pepper on thermogenesis in healthy adults: A systematic review and meta-analysis. Phytother Res. 2021;35(3):1358-1377. doi: 10.1002/ptr.6897.PubMedUsed to support: Systematic review/meta-analysis finding capsaicinoids/capsinoids significantly raised resting metabolic rate (~+34 kcal/day) and fat oxidation versus placebo, supporting the thermogenesis and energy-expenditure claims, though the absolute effect is small.
  3. Rossi PAQ, Lira FS, Bezerra VR, Clark NW, Fukuda DH, Panissa VLG. Acute Response to Capsiate Supplementation at Rest and during Exercise on Energy Intake, Appetite, Metabolism, and Autonomic Function: A Randomized Trial. J Am Nutr Assoc. 2022;41(6):541-550. doi: 10.1080/07315724.2021.1938294.PubMedUsed to support: Small acute randomized crossover trial of a capsaicinoid analogue (capsiate) at rest and during exercise where effects on appetite, energy intake, and metabolism were largely null/mixed, providing an honest counterweight to the appetite/energy-expenditure claims.
  4. Inoue N, Matsunaga Y, Satoh H, Takahashi M. Enhanced energy expenditure and fat oxidation in humans with high BMI scores by the ingestion of novel and non-pungent capsaicin analogues (capsinoids). Biosci Biotechnol Biochem. 2007;71(2):380-9. doi: 10.1271/bbb.60341.PubMedUsed to support: Small human RCT showing a single dose of capsinoids increased post-ingestion energy expenditure and fat oxidation in higher-BMI subjects, supporting the thermogenesis/fat-oxidation claims, though sample size is small and effects modest.